The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research

BACKGROUND: Rearranged during transfection (RET) fusion is a kind of uncommon mutation (about 1%) in non-small cell lung cancer (NSCLC). Although selective tyrosine kinase inhibitors (TKI) (selpercatinib and pralsetinib) have been available, there are no real-world data about the difference in the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Yan, Yang, Yilin, Fang, Yujia, Lin, Xinqing, Xie, Xiaohong, Deng, Haiyi, Wu, Jianhui, Zhou, Maolin, Sun, Ni, Xie, Zhanhong, Liu, Ming, Ouyang, Ming, Qin, Yinyin, Su, Chunxia, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176213/
https://www.ncbi.nlm.nih.gov/pubmed/35692799
http://dx.doi.org/10.3389/fonc.2022.864367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176213/
https://www.ncbi.nlm.nih.gov/pubmed/35692799
http://dx.doi.org/10.3389/fonc.2022.864367

Ejemplares similares